FBRX Stock Overview
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Forte Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.71 |
52 Week High | US$1.29 |
52 Week Low | US$0.38 |
Beta | 1.65 |
1 Month Change | 2.86% |
3 Month Change | -2.91% |
1 Year Change | -27.99% |
3 Year Change | -97.79% |
5 Year Change | n/a |
Change since IPO | -95.78% |
Recent News & Updates
Recent updates
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28Shareholder Returns
FBRX | US Biotechs | US Market | |
---|---|---|---|
7D | 7.5% | -0.5% | 0.6% |
1Y | -28.0% | 9.6% | 29.5% |
Return vs Industry: FBRX underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: FBRX underperformed the US Market which returned 29.8% over the past year.
Price Volatility
FBRX volatility | |
---|---|
FBRX Average Weekly Movement | 12.3% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FBRX's share price has been volatile over the past 3 months.
Volatility Over Time: FBRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 9 | Paul A. Wagner | https://www.fortebiorx.com |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Forte Biosciences, Inc. Fundamentals Summary
FBRX fundamental statistics | |
---|---|
Market cap | US$25.84m |
Earnings (TTM) | -US$31.48m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs FBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FBRX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$31.48m |
Earnings | -US$31.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.86 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did FBRX perform over the long term?
See historical performance and comparison